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Breast cancer genome-wide association studies (GWAS) have identified 150 genomic risk regions 20 
containing more than 13,000 credible causal variants (CCVs). The CCVs are predominantly 21 
noncoding and enriched in regulatory elements. However, the genes underlying breast cancer risk 22 
associations are largely unknown. Here, we used genetic colocalization analysis to identify loci at 23 
which gene expression could potentially explain breast cancer risk phenotypes. Using data from the 24 
Breast Cancer Association Consortium (BCAC) and quantitative trait loci (QTL) from the Genotype-25 
Tissue Expression (GTEx) project and The Cancer Genome Project (TCGA), we identify shared 26 
genetic relationships and reveal novel associations between cancer phenotypes and effector genes. 27 
Seventeen genes, including NTN4, were identified as potential mediators of breast cancer risk. For 28 
NTN4, we showed the rs61938093 CCV at this region was located within an enhancer element that 29 
physically interacts with the NTN4 promoter, and the risk allele reduced NTN4 promoter activity. 30 
Furthermore, knockdown of NTN4 in breast cells increased cell proliferation in vitro and tumor growth 31 
in vivo. These data provide evidence linking risk-associated variation to genes that may contribute 32 
to breast cancer predisposition. 33 
 34 
 35 
The influence of common genetic variation on gene expression underlies a considerable proportion 36 
of the heritability associated with complex traits. Mapping of expression QTL (eQTL), where genetic 37 
variants are tested for association with gene expression levels, is widely used to identify genes that 38 
are regulated by trait-associated variants. Several studies have shown that eQTLs are enriched in 39 
cell types relevant to the trait of interest1; 2. For example, T cell-specific eQTLs are over-represented 40 
for autoimmune risk alleles and monocyte-specific eQTLs for Alzheimer's [MIM: 104300] and 41 
Parkinson's [MIM: 168600] disease alleles2. For breast cancer [MIM: 114480], several studies have 42 
used eQTL data from tumor and normal tissues datasets to identify candidate target genes3-6. Recent 43 
studies have also showed that breast cancer risk variants could regulate genes in cells of the tumor 44 
microenvironment, such as immune cells and fibroblasts7; 8. Because eQTLs are widespread, overlap 45 
between GWAS and eQTL signals is likely to occur by chance when using nominal significance 46 
 3 
levels. To mitigate false positive findings it is therefore important to show that the same genetic 47 
signal underlies gene expression and disease susceptibility.  48 
 49 
Several statistical colocalization approaches have been developed to determine whether molecular 50 
traits (e.g. gene expression) and a disease trait share common causal variants. The simplest 51 
Bayesian model used in tools such as QTLMatch9 and COLOC10 tests for colocalization for two traits 52 
and determines whether they are driven by distinct variants or share a single causal signal. For 53 
example, Parker et al used COLOC to identify 32 emphysema-associated [MIM: 130700] regions 54 
where it is likely that colocalized GWAS and eQTL signals arise from the same causal variant11. 55 
Additional functional studies then showed that the emphysema-associated variant rs1690789 56 
regulates TGFB2 (encoding transforming growth factor beta 2 [MIM: 190220]) expression in human 57 
lung fibroblasts. A recent implementation of COLOC, called HyPrColoc (Hypothesis Prioritization in 58 
multi-trait Colocalization), identifies colocalized association signals using summary statistics on large 59 
number of traits12. This method has been used to identify regulatory loci underlying quantitative 60 
haematopoietic traits13. 61 
 62 
In this study, we extracted eQTL association effect estimates and standard errors for all variants at 63 
the 150 breast cancer risk loci previously analysed by BCAC14 (mean region size = 1.09 Mb). GWAS 64 
summary data were available for overall breast cancer risk from 122,977 cases and 105,974 65 
controls3; and for estrogen receptor negative (ER-) breast cancer risk from 21,468 cases and 66 
100,594 controls, combined with 18,908 BRCA1 mutation carriers (9414 with breast cancer)15 all of 67 
European ancestries. Variant IDs were converted to GRCH38 build co-ordinates and harmonized 68 
with GTEx data (0.86% failed conversion and were dropped from the analysis). The GTEx version 8 69 
release includes data from normal breast tissue from 396 individuals. GTEx eQTL association data 70 
for variants within 1 Mb windows of transcription start sites were extracted based on the variants 71 
present in the breast cancer risk data. Colocalization of the GWAS and eQTL signals were calculated 72 
using the HyPrColoc R package12. Breast cancer risk phenotypes and each proximal gene were 73 
analyzed separately with default parameters. Signals were considered to be plausibly colocalizing if 74 
posterior probability for colocalization (PPFC) > 0.7, resulting in a false discovery rate of 5%12.  75 
 4 
 76 
We identified 17 genes at 14 loci where the GTEx eQTL association P values are < 10-6 (Table 1). 77 
For every locus, all candidate SNPs met the GWAS significance P value threshold (5x10-8) for overall 78 
or ER- breast cancer risk (Table 1). For 11 loci (NTN4, PIDD1 [MIM: 605247], CBX8 [MIM: 617354], 79 
L3MBTL3 [MIM: 618844], RCCD1 [MIM: 617997], PRC1-AS1, SSBP4 [MIM: 607391], MARCH11 80 
[MIM: 613338], ZNF596, RP5-855D21.3 and RP11-53O19.1), the candidate colocalized SNPs have 81 
been previously nominated as strong candidate causal signals using multivariate logistic 82 
regression14 (Table 1 and Figure 1). However, at six loci (ATG10 [MIM: 610800], CCDC88C [MIM: 83 
611204], PPM1K [MIM: 611065], RP11-250B2.3, RP1-265C24.5 and RP11-250B2.5), the 84 
colocalized signals are independent secondary signals based on stepwise multinomial logistic 85 
regression analysis  (10−6 < P < 10−4)14. While this does not rule out causality, larger GWAS would 86 
be required to confirm genome-wide significance (Figure S1)14.  87 
 88 
Published computational predictions of target genes at breast cancer risk loci using the INQUISIT 89 
pipeline (which interrogates data including ChIA-PET, Hi-C, ChIP-seq and eQTL data independent 90 
of GTEx) provide further support for ten colocalized genes (Table S1)3; 14. Of these, NTN4, PIDD1, 91 
L3MBTL3 and RCCD1 have the strongest evidence from functional genomics data. Transcriptome-92 
wide association studies also suggest that 13 of the 17 genes are regulated by breast cancer risk 93 
variants5-7; 16; 17 (Table S1). Moreover, previous eQTL analysis based on TCGA breast tumor data 94 
have identified three of these candidate genes3; 14 (Figure S2). For three genes (PIDD1, L3MBTL3 95 
and SSBP4), CCVs are located in the promoter regions, and for PIDD1 previous reporter assays 96 
indicate the risk haplotype increases promoter activity3. Our recent capture Hi-C data showed also 97 
chromatin looping occurs between putative regulatory regions containing CCVs and the promoters 98 
of four genes (NTN4, PRC1-AS1, ATG10 and RP1-265C24.5) in breast cell lines18. For the remaining 99 
loci, multiple CCVs were located in the introns of target genes and/or intergenic regions, but lacked 100 
demonstrable CCV-gene interactions. It is possible that some cis-regulatory interactions are only 101 
detected in specific breast cell subpopulations, or that CCVs are acting through other mechanisms 102 
such as perturbation of pre-messenger RNA splicing or altered noncoding RNA stability, structure 103 
and/or function. Of note, three genes (PIDD1, CBX8, and L3MBTL3) contain breast cancer CCVs in 104 
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their exons which are predicted to change the amino acid sequence, thus we cannot rule out that 105 
these are functional variants that affect the protein product. 106 
  107 
One high probability colocalization signal, targeting NTN4, was detected at a locus at 12q22 (Table 108 
1, Figures 1 and 2). Genetic fine-mapping studies have identified one risk signal at 12q22 that 109 
contains two CCVs (rs61938093 and rs17356907; odds ratio = 1.094, r2 = 1)14. Both CCVs fall within 110 
putative regulatory elements (PREs) marked by open chromatin in B80T5 and MCF10A non-111 
tumorigenic breast cell lines (Figure 3A). The PREs map to a large intergenic region between 112 
USP44 [MIM: 610993] (encoding ubiquitin-specific protease 44) and NTN4 (encoding Netrin 4; 113 
Figure 3A). Using promoter capture HiC data18, we observed that the PREs frequently participate in 114 
long-range chromatin interactions with the NTN4 promoter in non-tumorigenic and tumorigenic 115 
breast cell lines (Figures 3A and S2A). Notably, no other eQTLs or chromatin interactions from the 116 
PRE to promoter regions were detected in the breast cell lines we examined (Figures 3A and 117 
S2A)18, suggesting NTN4 is the likely target gene at this signal.  118 
 119 
To determine how the PRE alters NTN4 transcriptional activity, we targeted a nuclease-defective 120 
dCas9 fused to the Kruppel-associated box (lentiviral vector pHR-SFFV-dCas9-BFP-KRAB; a gift 121 
from Stanley Qi & Jonathan Weissman, Addgene plasmid #46911) to the PRE. Two independent 122 
single-guide RNAs (sgRNAs) targeting the PRE were designed (Table S2) and cloned into the 123 
lentiviral vector pgRNA-humanized (a gift from Stanley Qi, Addgene plasmid #44248). Lentiviral 124 
particles were produced from HEK293 cells transfected with accessory plasmids pCMV-dR8.91 and 125 
pCMV-VSV-G (gifts from David Harrich, QIMR Berghofer), and with dCas9-KRAB or pgRNA 126 
constructs using Lipofectamine 2000 (Life Technologies). Supernatants from dCas9-KRAB and 127 
pgRNA cultures were mixed and transduced into Bre80-TERT1 breast cells. Cells expressing both 128 
dCas9-KRAB (co-expressing blue fluorescent protein) and pgRNA (co-expressing mCherry) were 129 
enriched by FACS on the Aria IIIu platform (Becton-Dickinson). Notably, silencing of the PRE 130 
significantly reduced NTN4 expression in Bre80-TERT1 cells, suggesting that the PRE acts as an 131 
transcriptional enhancer (Figure 3B).  132 
 133 
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The regulatory capability of the PRE, combined with the effects of the CCVs, was further examined 134 
in reporter assays. An NTN4 promoter-driven luciferase reporter construct was generated by the 135 
insertion of a PCR amplified genomic fragment into the KpnI/HindIII sites of pGL3-basic (Promega). 136 
A 1010 base pairs (bp) fragment containing a PRE1, with either the risk or protective alleles of 137 
rs61938093, or a 983 bp fragment containing a PRE2, with either the risk or protective alleles of 138 
rs17356907, were synthesized as gBlocks (Integrated DNA Technologies) and then cloned into the 139 
BamHI/SalI sites of the NTN4-promoter construct (genomic coordinates and primers are listed in 140 
Table S2). MCF10A and Bre80-TERT1 breast cells were transfected with the reporter constructs 141 
and luciferase activity was measured 24 h post-transfection using the Dual-Glo Luciferase System 142 
(Promega). To correct for any differences in transfection efficiency, Firefly luciferase activity was 143 
normalized to Renilla. Reporter assays confirmed strong enhancer activity of the PRE1 on the NTN4 144 
promoter in MCF10A and Bre80-TERT1 cells and inclusion of the rs6198093 risk allele significantly 145 
reduced NTN4 promoter activity (Figure 3C). In contrast, inclusion of PRE2 with the protective or 146 
risk alleles of rs17356907 had no significant effects on the NTN4 promoter activity. pGL3-promoter 147 
luciferase results ????  These results suggest that rs61938093 alters transactivation of NTN4, but it 148 
is possible that the CCVs also influence recruitment of key proteins required for chromatin looping 149 
between the enhancer and NTN4 promoter, which would not be observed in a reporter assay.  150 
 151 
To assess the potential impact of the CCVs on chromatin looping, quantitative allele-specific 3C was 152 
performed in heterozygous MCF10A and T47D breast cell lines. 3C libraries were generated using 153 
HindIII as previously described19. Three independent 3C libraries or genomic input DNA were 154 
amplified for 15 cycles with two separate xxxxx 3C specific or genomic DNA PCR primers (primers 155 
are listed in Table S2) and purified by QIAGEN columns. Allele-specific PCR products were then 156 
quantified using a custom TaqMan SNP genotyping assay for rs61938093 (Life Technologies) on 157 
the Rotor-Gene 6000 platform. Purified PCR products were Sanger sequenced by the Australian 158 
Genome Research Facility (AGRF). The results showed a preference for the protective t-allele 159 
(Figures 3D, 3E and S2B-S2E), indicating that risk alleles may abrogate looping between the 160 
enhancer and NTN4 which in turn may reduce NTN4 expression. 161 
 162 
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Electrophoretic mobility shift assays (EMSAs) then assessed transcription factor (TF) binding for the 163 
protective and risk alleles of the CCVs. Nuclear lysates were prepared from Bre80-TERT1 and 164 
MCF10A breast cells using the NE-PER nuclear and cytoplasmic protein extraction kit 165 
(ThermoFisher). Biotinylated oligonucleotides representing either the risk or protective allele were 166 
synthesized (Integrated DNA Technologies; Table S2) and annealed to form double-stranded 167 
duplexes. Duplex-bound complexes were resolved by electrophoresis in 10% (w/v) Tris-borate-168 
EDTA polyacrylamide (Lonza) and transferred to positively-charged nylon membranes by semi-dry 169 
transfer (Bio-Rad). Membranes were processed using the LightShift Chemiluminescent EMSA kit 170 
(ThermoFisher) and visualized with the C-DiGit blot scanner. The EMSAs showed that rs61938093 171 
and rs17356907 altered protein binding in vitro in Bre80-TERT1 and MCF10A cell lysates (Figures 172 
3F, S3A and S3B). In silico prediction tools including HaploReg20 and Alibaba221 predicted both 173 
CCVs to alter TF binding. However, EMSAs using competitor DNA against predicted and other 174 
breast-relevant TFs were unable to identify the specific protein(s) binding to the alleles (Figures 175 
S3C and S3D).  176 
 177 
We examined expression of NTN4 in matched normal and cancerous breast tissues using TCGA 178 
RNA-seq data. NTN4 was more highly expressed in normal tissue, a mixture of cell types, compared 179 
to adjacent tumor samples (Figure 4A) and is expressed across the histological subtypes, albeit 180 
with lower expression in the basal subtype (Figure 4B). To explore the effect of reduced NTN4 on 181 
breast cancer cell proliferation, MCF7 cells were transfected with ON-TARGETplus negative control 182 
or NTN4 siRNA smartpools (Dharmacon) using RNAiMAX (Life Technologies). NTN4 silencing was 183 
confirmed by TaqMan qPCR gene expression assay 72 h post-transfection (Figures S3E and S3F). 184 
Notably, NTN4 depletion promoted anchorage-dependent and -independent cell growth in MCF7 185 
cells (Figures 4C and 4D). To assess the effect of reduced NTN4 on tumor growth, we stably 186 
depleted NTN4 in MCF7 cells by targeting dCAS9-KRAB to the promoter of NTN4, and injected the 187 
cells in the mammary fat pad of nude mice. Female BALB/c-Foxn1nu/Arc mice were first 188 
subcutaneously implanted with 17β-estradiol (0.72 mg/pellet, 90 day release; Innovative Research 189 
of America) at 8 weeks of age. MCF7 control-CRISPRi or NTN4-CRISPRi cells were orthotopically 190 
injected into mammary fatpads 3 days later at 107 cells per mouse (6-7 mice per cell line). Tumor 191 
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volumes were measured every 2 days until experimental end, at which point mice were euthanized 192 
and their tumors excised and weighed. All animal procedures were conducted in accordance with 193 
Australian National Health and Medical Research regulations on the use and care of experimental 194 
animals, and approved by the QIMR Berghofer Medical Research Institute Animal Ethics Committee 195 
(P1499). Compared to control MCF7 cells containing non-targeting sgRNA, NTN4 depletion led to a 196 
marked increase in tumor growth (Figures 4E, 4F and S3G), which was reflected in increased tumor 197 
weight (Figure 4G).  198 
 199 
NTN4 encodes the Netrin-4 secreted protein which has been implicated in various developmental 200 
processes including axon guidance, angiogenesis, mammary and lung morphogenesis22. Several 201 
studies show that NTN4 is involved in cancer, but the exact role of NTN4 appears to be dependent 202 
on the cancer type. For example, NTN4 knockdown reduces cell proliferation and motility in gastric 203 
cancer [MIM: 613659] and melanoma [MIM: 155600]23; 24, but promotes cell migration and invasion 204 
in colorectal cancer [MIM: 114500] and breast cancer25; 26. NTN4 has also been implicated in breast 205 
cancer progression. For example, reduced NTN4 is reported to promote migration and invasion of 206 
breast cancer cells through epithelial to mesenchymal transition26. In addition, NTN4 has been 207 
shown to be an independent biomarker for prognosis of survival in breast cancer27; 28. We and others 208 
have demonstrated that SNPs can alter chromatin loop formation between promoters and 209 
enhancers29; 30. Here, we provide evidence that the same mechanism may explain how breast cancer 210 
CCVs alter NTN4 expression and that suppressed NTN4 increases cancer-related processes 211 
including cell proliferation and tumor growth. However, we acknowledge that further functional 212 
studies will be required to clarify how NTN4 contributes to breast tumor initiation.  213 
 214 
Seven additional colocalized target genes have prior evidence for a functional role in cancer. For 215 
example, PIDD1 (p53-induced death domain protein 1) is implicated in DNA-damage-induced 216 
apoptosis and tumorigenesis31. CBX8 is overexpressed in breast cancer and correlates with poor 217 
survival32. CBX8 functions by interacting with the H3K4 methyltransferase complex component 218 
WDR5 to activate genes involved in Notch signaling and promote breast tumorigenesis32. 219 
Furthermore, Guo et al showed ectopic ATG10 (autophagy related 10) overexpression decreases 220 
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colony formation of MDA-MB-231 breast cancer cells, suggesting it may play a role in breast 221 
tumorigenesis5. Notably, ten genes have no reported involvement in breast tumorigenesis and may 222 
represent new genes that influence the susceptibility to breast cancer. This list includes five lncRNAs 223 
which are arguably more challenging to investigate as they can have multiple functions. However, 224 
there is increasing evidence that dysregulated lncRNAs contribute to breast cancer etiology29; 33; 34. 225 
 226 
In summary, we used eQTL colocalization to link breast cancer risk variants to seventeen target 227 
genes, including some potential cancer driver genes, but many with no reported role in breast cancer 228 
etiology. However, even with demonstration of shared genetic signals, it is as yet unknown how 229 
genes implicated by statistical colocalization analyses reflect true molecular mechanisms. It is 230 
therefore important to perform functional assays, as we have done for NTN4, to provide evidence 231 
that the variant affects gene expression and the gene plays a role in the disease etiology. Future 232 
work confirming the role of these genes or associated pathways in breast cancer development could 233 
ultimately lead to new avenues for breast cancer prevention or therapy. 234 
 235 
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FIGURE LEGENDS 374 
Figure 1. Comparison of association signals from BCAC and GTEx v8 for breast tissue. 375 
LocusCompare plots35 for eleven high-probability colocalized signals. Gene names and the relevant 376 
breast cancer phenotypes are shown in the plot headings. Points are coloured based on linkage 377 
disequilibrium (LD) bins relative to the candidate SNP prioritized by HyPrColoc (purple diamond 378 
labelled with rsID; red: ≥ 0.8, orange: 0.6 – 0.8, green: 0.4 – 0.6, light blue: 0.2 – 0.4, and dark blue: 379 
< 0.2). LD data from 1000 Genomes phase 3, version 5 were retrieved from the LDlink portal36. 380 
Strong candidate causal variants for breast cancer risk are annotated as small diamonds and weaker 381 
secondary risk variants as squares. 382 
 383 
Figure 2. Regional association plots at the 12q22 breast cancer risk locus. Single variant 384 
associations with overall breast cancer risk (top panel) and with NTN4 expression in normal breast 385 
tissue from GTEx v8 (lower panel). Variants are represented by points colored relative to linkage 386 
disequilibrium (LD) with the candidate variant detected by HyPrColoc (rs17356907; red: ≥ 0.8, 387 
orange: 0.6 – 0.8, green: 0.4 – 0.6, light blue: 0.2 – 0.4, and dark blue: < 0.2).  388 
 389 
Figure 3. Breast cancer CCVs distally regulate NTN4. (A) WashU genome browser showing 390 
topologically associating domains (TADs) as horizontal gray bars above GENCODE annotated 391 
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coding genes (blue). The promoter capture Hi-C (PCHi-C) baits are depicted as black boxes. The 392 
putative regulatory element (PRE) containing the CCVs is shown as red colored vertical lines. The 393 
ATAC-seq tracks for B80T5 and MCF10A breast cells are shown as blue histograms. PCHi-C 394 
chromatin interactions are shown as black arcs. Red arcs depict chromatin looping between CCVs 395 
and the NTN4 promoter region. (B) dCAS9-KRAB was targeted to the PRE using two different 396 
sgRNAs (sgPRE1 and sgPRE2) in Bre80-TERT1 breast cells. SgCON contains a non-targeting 397 
control guide RNA. Gene expression was measured by qPCR and normalized to beta-glucuronidase 398 
(GUSB) expression. Error bars, SEM (n=3). P-values were determined by one-way ANOVA followed 399 
by Dunnett’s multiple comparisons test (**p < 0.01). (C) Luciferase reporter assays following 400 
transient transfection of MCF10A and Bre80-TERT1 breast cells. A PRE1 containing the protective 401 
(Prot.) or risk alleles of rs61938093 and a PRE2 containing the protective (Prot.) or risk alleles of 402 
rs1735907 were cloned into NTN4-promoter driven luciferase constructs. Error bars, SEM (n=3). P-403 
values were determined by two-way ANOVA followed by Dunnett’s multiple comparisons test (**p < 404 
0.01, ****p < 0.0001). (D,E; left panels) 3C interaction profiles between the NTN4 promoter and the 405 
genomic region containing the PRE in MCF10A (D) and T47D (E) 3C libraries generated with HindIII. 406 
A physical map of the region interrogated by 3C is shown above; the blue shading represents the 407 
position of the PRE and the anchor point set at the NTN4 promoter. Representative 3C profiles are 408 
shown. Error bars, SD (n=3). (D,E; right panels) Allele-specific qPCR to quantify the allelic ratio at 409 
CCV rs61938093. Error bars, SEM (n=3). P-values were determined using a Student’s t-test (***p < 410 
0.001). (F) EMSA for oligonucleotide duplexes containing CCVs rs61938093 or rs17356907 with 411 
either the risk allele (R) or protective allele (P) as indicated, assayed using Bre80-TERT1 nuclear 412 
extracts. Competitor oligonucleotides are listed above each panel and were used at 100-fold molar 413 
excess: (-) no competitor; (Neg) a non-specific competitor; (Self) an identical oligonucleotide with no 414 
biotin label. Red arrowheads indicate band mobility differences between alleles. 415 
 416 
Figure 4. NTN4 depletion promotes breast cell proliferation and tumor formation. (A) Boxplot 417 
showing NTN4 expression in normal breast and paired tumor tissue samples from TCGA. Boxplots 418 
indicate median (centre line), interquartile range (box limits) and range (whiskers). P-value was 419 
determined using a two-tailed t-test. (B) Boxplot showing NTN4 expression in breast tumors from 420 
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TCGA stratified by PAM50 molecular subtypes (n=841). Boxplots indicate median (centre line), 421 
interquartile range (box limits) and range (whiskers). (C) Proliferation of MCF7 cells transfected with 422 
a non-targeting control (siCON) or NTN4 (siNTN4) ON-TARGETplus siRNAs. Cells were grown in 423 
24-well plates and confluency of the wells was measured by the IncuCyte live-cell imaging system. 424 
Results represent relative cell growth rates. Error bars, SD (n=2). P-value was determined by 425 
Student’s t-test comparing confluency at the last time point measured (***p < 0.001). (D) MCF7 cells 426 
were transfected with the siCON or siNTN4 and grown over 7 days in ultra low-attachment 427 
conditions. Cell growth was assessed using the CellTiter-Glo luminescent cell viability assay. Graph 428 
shows fold change in luminescence of siNTN4 treated cells relative to siCON treated cells. Error bar, 429 
SEM (n=3). P-value was determined by Student’s t-test test (**p < 0.01). (E) MCF7-control (PgCON) 430 
or MCF7-dCas9-KRAB NTN4 repressed cells (SgNTN4-P1/P2) were orthotopically injected into the 431 
mammary fat pads of nude mice. Tumor growth curves for each group are shown. Values are shown 432 
as average tumor volumes at each time point. Error bars, SEM (n=6-7 mice per group). (F) Tumors 433 
of individual mice were dissected at day 38 post-injection. The scale bars represent 1 cm. (G) Plot 434 
of the individual weights of tumors with mean and SEM shown by cross-bar and error bars. (E, G) 435 
Mann-Whitney U test was used to compare differences between groups (*p < 0.05, **p < 0.01, ***p 436 
< 0.001).  437 
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Table 1. Candidate breast cancer risk genes identified by eQTL colocalization analyses. 438 
 439 


















ENSG00000074527.11 NTN4 Overall risk chr12:95527759-96527759 0.9466 rs17356907 0.97 8.01E-09 1.02E-39 
ENSG00000141570.10 CBX8 Overall risk chr17:77281387-78281725 0.9178 rs9905914 0.49 7.92E-23 4.00E-09 
ENSG00000198945.7 L3MBTL3 Overall risk chr6:129849119-130849119 0.7998 rs7740107 1.00 5.88E-40 2.90E-11 
ENSG00000183654.8 MARCH11 Overall risk chr5:15687358-16687528 0.8369 rs1013018 0.16 3.05E-09 1.65E-11 
ENSG00000177595.17 PIDD1 Overall risk chr11:303017-1303017 0.9695 rs6597981 0.22 6.53E-27 1.35E-12 
ENSG00000166965.12 RCCD1 Overall risk chr15:91009215-92009215 0.9633 rs113343095 0.60 2.44E-24 3.37E-15 
ENSG00000130511.15 SSBP4 Overall risk chr19:18050434-19071141 0.7800 rs7258465 0.09 7.87E-08 2.79E-28 
ENSG00000172748.13 ZNF596 ER- risk chr8:0-670692 0.9059 rs35346588 0.79 2.17E-08 1.39E-08 
ENSG00000258725.1 PRC1-AS1* Overall risk chr15:91009215-92009215 0.9302 rs2290202 0.22 5.89E-10 1.87E-15 
ENSG00000251141.5 RP11-53O19.1* Overall risk chr5:44013304-45206498 0.9347 rs10941679 1.00 4.41E-07 5.61E-73 
ENSG00000272812.1 RP5-855D21.3* ER- risk chr8:0-670692 0.9769 rs3008281 0.81 6.11E-08 6.23E-09 
ENSG00000152348.15 ATG10# Overall risk chr5:80928261-82038046 0.7904 rs144580806 0.36 2.56E-40 8.07E-12 
ENSG00000015133.18 CCDC88C# Overall risk chr14:91341069-92368623 0.9465 rs8018155 0.50 9.15E-11 4.03E-12 
ENSG00000163644.14 PPM1K# Overall risk chr4:88743818-89743818 0.9935 rs10022462 0.58 1.60E-08 1.55E-09 
ENSG00000233967.6 RP11-250B2.3*# Overall risk chr6:80594287-81594287 0.8473 rs9448940 0.22 4.65E-11 9.85E-09 
ENSG00000260645.1 RP11-250B2.5*# Overall risk chr6:80594287-81594287 0.8227 rs1436864 0.08 1.97E-08 3.89E-09 
ENSG00000219392.1 RP1-265C24.5*# Overall risk chr6:26180698-27180698 0.9901 rs35768595 0.38 5.95E-10 3.16E-09 
 440 
* Noncoding RNAs 441 
# Weaker secondary signals14 442 
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